Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Arthritis Care Res (Hoboken). 2021 Dec 17;74(1):151–160. doi: 10.1002/acr.24433

Table 4.

Agreement between MDA definitions and Clinical Disease Activity in Psoriatic Arthritis (cDAPSA) T2T state (cDAPSA≤13) across all visits

Agreement* MDA PROMIS-PF 4a MDA PROMIS-PF CAT cDAPSA T2T (≤13)
MDA HAQ-DI
Kappa
(95% CI)
N
0.90
(0.84-0.95)
301
0.94
(0.90-0.97)
303
0.70
(0.62-0.77)
299
MDA PROMIS-PF4a
Kappa
(95% CI)
N		 -
0.96
(0.93-0.99)
307
0.67
(0.59-0.75)
303
MDA PROMIS-PF CAT
Kappa
(95% CI)
N		 - -
0.71
(0.63-0.78)
305
*

Bias corrected 95% confidence intervals for the kappa statistic were calculated using bootstrapping with 2000 repetitions of individual patients.

Abbreviations

CI confidence interval; HAQ-DI: Heath Assessment Questionnaire-Disability Index; PROMIS-PF 4a: Patient Reported Outcomes Measurement Information System Short Form v2.0 Physical Function 4a; PROMIS-PF CAT: PROMIS Bank v1.2 - Physical Function Computer Adaptive Test; MDA HAQ-DI: Minimal disease activity that includes the HAQ-DI ≤0.5 criterion; MDA PROMIS-PF4a includes the PROMIS-PF4a T-score ≥41.3 criterion; MDA PROMIS-PF CAT includes the PROMIS-PF CAT T-score ≥41.3 criterion; cDAPSA: Clinical disease activity in psoriatic arthritis; T2T: treat-to-target.